XTX Topco Ltd Makes New $330,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Key Points

• XTX Topco Ltd has acquired a new stake in Dyne Therapeutics, Inc., purchasing 31,574 shares valued at approximately $330,000.
• Several institutional investors, including Y Intercept Hong Kong Ltd and GSA Capital Partners LLP, have also increased their positions in Dyne Therapeutics during the 1st quarter.
• Analysts have mixed ratings on Dyne Therapeutics with a consensus rating of "Moderate Buy" and a target price of $34.94, despite recent price target reductions from several firms.

XTX Topco Ltd acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,574 shares of the company's stock, valued at approximately $330,000.

A number of other large investors have also recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $2,340,000. Rhumbline Advisers grew its holdings in Dyne Therapeutics by 4.2% in the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after buying an additional 5,383 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Dyne Therapeutics by 54.5% in the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after buying an additional 13,677 shares during the last quarter. GAMMA Investing LLC increased its position in Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after buying an additional 2,345 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Dyne Therapeutics by 7.7% during the fourth quarter. Northern Trust Corp now owns 777,013 shares of the company's stock worth $18,306,000 after buying an additional 55,511 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DYN shares. Evercore ISI restated an "outperform" rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Robert W. Baird decreased their price target on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 18th. Sanford C. Bernstein initiated coverage on shares of Dyne Therapeutics in a research report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective for the company. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Finally, Chardan Capital decreased their target price on Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $34.94.

Insiders Place Their Bets

In other news, CEO John Cox bought 100,000 shares of the stock in a transaction dated Monday, July 14th. The stock was bought at an average cost of $9.11 per share, with a total value of $911,000.00. Following the purchase, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This represents a 70.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 20.77% of the stock is owned by company insiders.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded up $0.62 during midday trading on Wednesday, reaching $12.24. The company's stock had a trading volume of 2,902,855 shares, compared to its average volume of 2,652,978. The business's fifty day simple moving average is $10.56 and its 200-day simple moving average is $11.30. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The company has a market capitalization of $1.74 billion, a P/E ratio of -3.17 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.